The therapeutic effects of anti-VEGF-A and anti-angiogenic factors in experimental diabetic nephropathy have been reported, including amelioration of increases in urinary albumin excretion, glomerular volume, glomerular basement membrane thickening, in addition to decreased slit pore density and nephrin quantity [36–38]. This evidence concerns the gene VEGFA and diabetic kidney disease.